Replies to post #259628 on Amarin Corp Plc (AMRN)

[Sluicebox]

We won the label right, but lost the patent. While in appeal I believe generics can file sANDA and if approved by FDA launch at risk of the patent appeal being won by Amarin. That is unless Amarin gets an injunction granted against generics launching, during the appeal. I believe only then we will have until 2022.

If we win the patent case, we most likely will have an appeal from generics on the label verdict and have to fight that too, before we can declare us winner and get on with the sales of Vascepa.

[HDGabor]

r-

Then any generics will have to challenge not just the Marine patents but the Reduce-It patents as well

Nope … generics do not have to challenge Reduce-It patents … do not have to include R-IT indication in the label (see more: Paragraph VIII notice … "carve-out")

Best,
G